{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(5)"],"submitter":["Emdina A"],"pubmed_abstract":["Biomarkers are increasingly recognized as tools in the diagnosis and prognosis of neurodegenerative diseases. No fluid biomarker for Parkinson's disease (PD) has been established to date, but α-synuclein, a major component of Lewy bodies in PD and dementia with Lewy bodies (DLB), has become a promising candidate. Here, we investigated CSF α-synuclein in patients with PD (<i>n</i> = 28), PDD (<i>n</i> = 8), and DLB (<i>n</i> = 5), applying an electrochemiluminescence immunoassay. Median values were non-significantly (<i>p</i> = 0.430) higher in patients with PDD and DLB (287 pg/mL) than in PD (236 pg/mL). A group of <i>n</i> = 36 primarily non-demented patients with PD and PDD was clinically followed for up to two years. A higher baseline α-synuclein was associated with increases in Hoehn a"],"journal":["Diagnostics (Basel, Switzerland)"],"pagination":["1259"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9140902"],"repository":["biostudies-literature"],"pubmed_title":["Baseline Cerebrospinal Fluid α-Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline."],"pmcid":["PMC9140902"],"pubmed_authors":["Maass F","Llorens F","Bunck T","Goebel S","Kruse N","Zerr I","Schmitz M","Lingor P","Mollenhauer B","Varges D","Emdina A","Nuhn S","Hermann P"],"additional_accession":[]},"is_claimable":false,"name":"Baseline Cerebrospinal Fluid α-Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline.","description":"Biomarkers are increasingly recognized as tools in the diagnosis and prognosis of neurodegenerative diseases. No fluid biomarker for Parkinson's disease (PD) has been established to date, but α-synuclein, a major component of Lewy bodies in PD and dementia with Lewy bodies (DLB), has become a promising candidate. Here, we investigated CSF α-synuclein in patients with PD (<i>n</i> = 28), PDD (<i>n</i> = 8), and DLB (<i>n</i> = 5), applying an electrochemiluminescence immunoassay. Median values were non-significantly (<i>p</i> = 0.430) higher in patients with PDD and DLB (287 pg/mL) than in PD (236 pg/mL). A group of <i>n</i> = 36 primarily non-demented patients with PD and PDD was clinically followed for up to two years. A higher baseline α-synuclein was associated with increases in Hoehn a","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-26T02:46:19.524Z","creation":"2025-02-19T02:16:27.333Z"},"accession":"S-EPMC9140902","cross_references":{"pubmed":["35626415"],"doi":["10.3390/diagnostics12051259"]}}